Designing Benefits and Payment Models for Innovative High-Investment Medications - Proceedings from the AMCP Partnership Forum
Webinar Recorded on March 12, 2019
High-investment medications, such as gene therapy and innovative specialty medications, offer breakthrough treatments that can greatly improve outcomes for patients with serious health conditions. Such innovative treatments have higher short-term costs, compared with current standards of care, but are anticipated to deliver substantial benefits that may persist over a long period of time, such as reduced mortality, improved health and quality of life, reduced health care costs, improved productivity, and reduced disability. This webinar presents proceedings of the July 2018 AMCP Partnership Forum, Designing Benefits and Payment Models for Innovative High-Investment Medications, during which a diverse group of AMCP members and stakeholders discussed new benefit designs and payment models to address potential concerns.
- Susan Trieu, PharmD
Director, Enterprise Specialty Clinical Solutions, MedImpact Healthcare Systems, Inc.
- Jane Barlow, MD, MPH, MBA
Chief Clinical Officer, Real Endpoints
- Stephen George, PharmD, MS
Senior Consultant, Milliman